Skip to main content

Table 3 Clinicopathologic parameters of the patients and hyperfibrinogenemia

From: Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients

Parameters

Hyperfibrinogenemia

P-value

Yes

No

Age

<56(362)

177(48.9 %)

185(51.1 %)

0.117

≥56(362)

155(42.8 %)

207(57.2 %)

FIGO Stage

Early(62)

12(19.4 %)

50(80.6 %)

<0.001

Advanced(662)

320(48.3 %)

342(51.7 %)

CA125 Level

<500U/ml(157)

53(33.8 %)

104(66.2 %)

0.001

≥500U/ml(556)

272(48.9 %)

284(51.1 %)

Ascitesa

No(85)

21(24.7 %)

64(75.3 %)

<0.001

<500 ml(122)

22(18.0 %)

100(82.0 %)

≥500 ml(723)

289(56.0 %)

227(44.0 %)

Cytoreductionb

R0(231)

70(30.3 %)

161(69.7 %)

<0.001

R1(358)

179(50.0 %)

179(50.0 %)

R2(135)

83(61.5 %)

52(38.5 %)

Chemosensitivity

Yes(474)

186(39.2 %)

288(60.8 %)

<0.001

No(197)

118(59.5 %)

79(40.1 %)

  1. aSubgroup analyses: PNo vs <500ml = 0.296, PNo vs >500ml < 0.001, P<500 ml vs <500ml < 0.001
  2. bSubgroup analyses: PR0 vs R1  < 0.001, PR0 vs R2 < 0.001, PR1 vs R2 = 0.026